Radio Electric Asymmetric Conveyer: A Novel Neuromodulation Technology in Alzheimer’s and Other Neurodegenerative Diseases

Abstract

Global research in the field of pharmacology has not yet found effective drugs to treat Alzheimer’s disease (AD). Thus, alternative therapeutic strategies are under investigation, such as neurostimulation by physical means. Radio electric asymmetric conveyer (REAC) is one of these technologies and has, until now, been used in clinical studies on several psychiatric and neurological disorders with encouraging results in the absence of side effects. Moreover, studies at the cellular level have shown that REAC technology, with the appropriate protocols, is able to induce neuronal differentiation both in murine embryonic cells and in human adult differentiated cells. Other studies have shown that REAC technology is able to positively influence senescence processes. Studies conducted on AD patients and in transgenic mouse models have shown promising results, suggesting REAC could be a useful therapy for certain components of AD.

The Compression Flow as a Measure to Estimate the Brain Connectivity Changes in Resting State fMRI and 18FDG-PET Alzheimer's Disease Connectomes

“…Besides the clinical involvements of the CF as neuroimaging biomarker, the fundamental assumptions on which the method is based could shed new insights in the comprehension of AD (Rinaldi et al, 2015 ). The integration of information represents one of the most important information processing stage of the brain and aberrations of information integration are reported in a plethora of diseases.…”

REAC neurobiological treatments in acute post-traumatic knee medial collateral ligament lesion

“…The REAC is a technology platform for biomodulation [ 35 , 41 ] and neuromodulation [ 20 , 24 , 33 ] treatments. The REAC technology device used in this clinical investigation was a BENE 110 model (ASMED, Florence, Italy).…”

“…In the field of biomodulation, specific tissue optimization (TO) treatment protocols with REAC technology are effective not only in post-traumatic outcomes [ 25 , 26 ], regenerative medicine [ 27 , 28 , 29 ], and in neurodegenerative diseases [ 30 , 31 , 32 , 33 ], but also in direct cellular reprogramming [ 34 , 35 , 36 ]. TO treatments have been used for years, both in human and veterinary medicine, in the treatment of post-traumatic lesions in various types of tissues, as muscle, ligament and tendon; nevertheless, scientific work on this topic had never been produced to date.…”

Effects of regenerative radioelectric asymmetric conveyer treatment on human normal and osteoarthritic chondrocytes exposed to IL-1β. A biochemical and morphological study

“…The REAC is an innovative patented technology9,10 for biostimulation and/or bioenhancement that induces weak radioelectric currents in tissue, to induce cell-reprogramming activity 12. The model used in this study (BENE Bio Enhancer – Neuro Enhancer ® ; ASMED, Florence, Italy) is specifically designed for regenerative treatments.…”

“…Identification of a tool capable of counteracting the cartilage degeneration occurring during OA without side effects could represent an interesting approach in OA therapy. In this regard, we have recently observed that Regenerative Tissue Optimization (TO-RGN) treatment with radioelectric asymmetric conveyer (REAC) technology9,10 significantly influenced the differentiation capability of mouse embryonic stem cells11 as well as the pluripotency and plasticity of human skin-derived fibroblasts 12. These findings have suggested the purpose of this study – to clarify whether the positive effect of REAC TO-RGN might be related to a capability to counteract the IL-1β-induced signaling pathway, a primary cause of OA.…”